The clinical impact of a urinary tract infection management bundle in a tertiary-care teaching hospital

2018 ◽  
Vol 40 (1) ◽  
pp. 72-78 ◽  
Author(s):  
Timothy D. MacLaggan ◽  
Christopher P. Le ◽  
Kristen A. Iverson ◽  
Chelsey L. Ellis ◽  
Jacques Allard ◽  
...  

AbstractObjectiveThe aim of this study was to assess the impact of a urinary tract infection (UTI) management bundle to reduce the treatment of asymptomatic bacteriuria (AB) and to improve the management of symptomatic UTIs.DesignBefore-and-after intervention study.SettingsTertiary-care hospital.PatientsConsecutive sample of inpatients with positive single or mixed-predominant urine cultures collected and reported while admitted to the hospital.MethodsThe UTI management bundle consisted of nursing and prescriber education, modification of the reporting of positive urine cultures, and pharmacists’ prospective audit and feedback. A retrospective chart review of consecutive inpatients with positive urinary cultures was performed before and after implementation of the management bundle.ResultsPrior to the implementation of the management bundle, 276 patients were eligible criteria for chart review. Of these 276 patients, 165 (59·8%) were found to have AB; of these 165 patients with AB, 111 (67·3%) were treated with antimicrobials. Moreover, 268 patients met eligibility criteria for postintervention review. Of these 268, 133 patients (49·6%) were found to have AB; of these 133 with AB, 22 (16·5%) were treated with antimicrobials. Thus, a 75·5% reduction of AB treatment was achieved. Educational components of the bundle resulted in a substantial decrease in nonphysician-directed urine sample submission. Adherence to a UTI management algorithm improved substantially in the intervention period, with a notable decrease in fluoroquinolone prescription for empiric UTI treatment.ConclusionsA UTI management bundle resulted in a dramatic improvement in the management of urinary tract infection, particularly a reduction in the treatment of AB and improved management of symptomatic UTI.

Author(s):  
Shobha Kl ◽  
Ramachandra L ◽  
Amita Shobha Rao ◽  
Anand Km ◽  
Gowrish Rao S

  Objectives: Pseudomonas species cause urinary tract infection (UTI). This study was conducted to isolate Pseudomonas species causing significant bacteriuria and to analyze its antibiogram at a tertiary care hospital.Methods: About 107 urine samples received in the laboratory from August 2015 to July 2016 having significant bacteriuria with Pseudomonas species were tested for antimicrobial activity. Samples were from both inpatients and patients attending as outpatients to a tertiary care hospital with different age groups and gender. Midstream urine samples were inoculated using a standard calibrated loop into blood agar and MacConkey agar following semi quantitative technique using Kass concept. MALD (Biomerio, ElToile, France) was used for speciation, and Vitex automated system (Biomerio, ElToile, France) was used for antibacterial sensitivity testing.Results: About 107 urine samples contained Pseudomonas species by MALDI obtained from 69 male (64.48%) and 38 (35.51%) female patients. Inpatients were 90 (84.11%) and 17 (15.88%) outpatient department (OPD) patients. Isolation of Pseudomonas aeruginosa was from 90 samples (84.11%) and Pseudomonas putida in 17 (15.88%). Significant bacteriuria was more in the age group of ˃60 years in both genders. Susceptibility to gentamicin was 52 (48.59%), ceftazidime 56 (52.33%), and imipenem was 58 (54.20%). Organism was multidrug resistant in 49 (45.79%) samples.Conclusion: P. aeruginosa remains the most common uropathogen among Pseudomonas species. Drug of choice for inpatients suffering from UTI by Pseudomonas species can be gentamicin and for patients attending OPD can be ceftazidime. Imipenem can be the reserve drug. Periodic antibiotic review is required for proper treatment of UTI.


Sign in / Sign up

Export Citation Format

Share Document